Suzhou Forlongbiotech

Suzhou Forlong Biotech is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to the discovery and development of innovative peptide therapeutics. The company focuses on metabolic diseases, particularly obesity and type 2 diabetes, utilizing its expertise in long-acting peptide technology and multi-target agonist design. Its lead candidate, FL-001, is a dual GLP-1/GIP receptor agonist currently in clinical development for weight management. Forlong Biotech also maintains a pipeline of triple agonists and other peptide-based molecules targeting NASH and cardiovascular conditions. In addition to its internal drug discovery programs, the company provides specialized peptide synthesis and optimization services to global partners. The firm leverages a proprietary platform for peptide modification to enhance the half-life and efficacy of its therapeutic candidates.